Volume 14 Supplement 1
Canadian Anxiety Disorders Guidelines Initiative: Clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Edited by Mark Powers
Unrestricted educational grants for the development of these guidelines and publication of this supplement were provided by Astra Zeneca Canada, Eli-Lilly Canada, Janssen Inc, Lundbeck Canada, Pfizer Canada, Purdue Canada, Servier Canada Inc, Shire Canada and Valeant Canada. None of the members received payment for participating in the development of these guidelines. The article has undergone the journal's standard peer review process for supplements. The Supplement Editor is funded by a grant from the National Institute on Drug Abuse K01 DA035930 and declares that he has no other competing interests.
Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.